Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2001
We are writing in regard to the article by Vargas et al1 entitled "A Pilot Study Evaluating the Treatment of Postparotidectomy Sialoceles with Botulinum Toxin Type A [BoNT/A]," which was published in the March 2000 issue of the ARCHIVES. In accordance with the experience of Vargas and colleagues, my coworkers and I recently reported our results using BoNT/F to treat a parotid sialocele.2 Therefore, we believe that BoNT serotypes other than type A should be considered for use in patients who do not respond to treatment with BoNT/A. In 1995, Drobik and Laskawi3 suggested using BoNT/A to treat patients affected by gustatory sweating, or Frey syndrome. The goal was the reduction of facial sweating by the determination of a cholinergic autonomic block.
Tugnoli V, Anna AS, Ragona RM, Eleopra R, De Grandis D, Montecucco C. Treatment of Frey Syndrome With Botulinum Toxin Type F. Arch Otolaryngol Head Neck Surg. 2001;127(3):339-340. doi: